ARCHIVES

In Brief: NCI To Supply Maytansine For Several Phase I Studies; Holleb Urges Referrals To “Experts”

This article is from The Cancer Letter archive.

Vol. 02 No. 13 | March 26, 1976

Download PDF Visit The Full Archive

Related Articles

Rising Costs at NCI Threaten To Overtake Slim Increases In Budget Appropriations

March 28, 2014

NCI Plans Preclinical Studies Of Endoxifen, A Tamoxifen Metabolite.

August 7, 2009

Joe Gray Moves To OHSU Knight Cancer Institute

January 21, 2011

In Brief: Congresswomen Receive FASEB Awards for Public Service for Support of NIH

May 2, 1997

House Committee Aims To Cut Markup On Office-Administered Cancer Drugs.

November 16, 2001

CCIRC Report Suggests Ways To Enhance Role Of Surgeons

July 22, 1977